ISICEM: Albumin does not improve survival in sepsis

ISICEM: albumin does not improve survival in sepsis

(HealthDay)—For patients with severe sepsis in intensive care units, the use of albumin replacement in addition to crystalloid solution does not improve survival, according to a study published online March 18 in the New England Journal of Medicine. This research was published to coincide with the International Symposium on Intensive Care and Emergency Medicine, held from March 18 to 21 in Brussels.

Pietro Caironi, M.D., Ph.D., from the Università degli Studi di Milano, and colleagues randomized 1,818 patients with in 100 units to receive 20 percent albumin and crystalloid solution or crystalloid solution alone.

The researchers found that, compared with those in the crystalloid group, patients in the albumin group had a higher mean arterial pressure (P = 0.03) and lower net fluid balance (P < 0.001) during the first seven days. There was no significant between-group difference in the total daily amount of administered fluid (P = 0.10). At 28 days, 31.8 percent of the albumin group and 32.0 percent of the crystalloid group had died (relative risk in albumin group, 1.00; P = 0.94). Mortality at 90 days was 41.1 and 43.6 percent, respectively (relative risk, 0.94; P = 0.29).

"In with severe sepsis, albumin replacement in addition to crystalloids, as compared with crystalloids alone, did not improve the rate of survival at 28 and 90 days," the authors write.

The study was funded by the Italian Medicines Agency.

More information: Abstract
Full Text
More Information

add to favorites email to friend print save as pdf

Related Stories

Albumin improves bacterial peritonitis outcomes

Feb 07, 2013

(HealthDay)—For patients with spontaneous bacterial peritonitis (SBP), albumin infusion is associated with reduced renal impairment and decreased mortality, according to research published in the February ...

Ringer's acetate better for patients with severe sepsis

Jun 28, 2012

(HealthDay) -- Fluid resuscitation with hydroxyethyl starch (HES) 130/0.4 for patients with severe sepsis leads to an increased risk of death at day 90 and an increased likelihood of requiring renal-replacement ...

Recommended for you

Ebola: Keeping patients alive as body fights back

8 hours ago

People who shared an apartment with the first U.S. Ebola patient are emerging from quarantine healthy. And while Thomas Eric Duncan died and two U.S. nurses were infected caring for him, there are successes, ...

Study suggests altering gut bacteria might mitigate lupus

9 hours ago

Lactobacillus species, commonly seen in yogurt cultures, correlate, in the guts of mouse models, with mitigation of lupus symptoms, while Lachnospiraceae, a type of Clostridia, correlate with worsening, according to researc ...

User comments